Apple Turns 50: From Garage Startup to AI Crossroads 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
SMIC Allegedly Supplies Chipmaking Tools to Iran's Military, U.S. Officials Warn 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Brown-Forman and Pernod Ricard in Merger Talks to Create World's Largest Spirits Giant 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Unilever and Magnum Face Defamation Lawsuit Over Ben & Jerry's Board Chair Dismissal 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
CAMBRIDGE, Mass., Jan. 03, 2017 -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that Robert Bazemore, chief executive officer of Epizyme, will present a company overview at the J.P. Morgan 35th Annual Healthcare Conference on Monday, January 9, 2017 at 12:00 p.m. PT. The conference is taking place January 9-12, 2017 at the Westin St. Francis in San Francisco.
To access the live webcast of Epizyme’s presentation, please visit the Events & Presentations page within the Investor page of the website at www.epizyme.com. Replays of the webcast will be available on the Epizyme website for 90 days following the conference.
About Epizyme, Inc.
Epizyme, Inc. is a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients. Epizyme has built a proprietary product platform that the Company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients. For more information, visit www.epizyme.com.
Media Contact: Julie DiCarlo, Epizyme, Inc. (617) 306-5823 [email protected] Investor Contact: Monique Allaire, THRUST Investor Relations (617) 895-9511 [email protected]
